230results about "Chemokines" patented technology

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

The invention belongs to the field of tumor drug research, and particularly relates to a cell vesicle co-delivery system, an anti-tumor drug and application. The cell vesicle-like co-delivery system is constructed according to the following steps: co-transfecting a recombinant expression vector of tumor targeting protein or targeting peptide and a recombinant plasmid of circRNA of effector molecules related to pyroptosis to a tool cell, and collecting to obtain the cell vesicle-like co-delivery system, a recombinant expression vector of the tumor targeting protein or the targeting peptide contains a DNA sequence for coding MCP protein, and a recombinant plasmid of circRNA of an effector molecule related to pyroptosis contains a DNA sequence for coding MS2 protein. According to the cell vesicle co-delivery system provided by the invention, tumor cell death is directly induced by delivering the cell death related effector molecule RNA through the cell vesicles, the killing efficiency is high, the side effect is relatively small, and the problems of mass production and drug loading can be solved.

Provided herein, inter alia, are oncolytic viruses that express recombinant proteins having bispecific activity. The recombinant proteins include a first fusion protein comprising a first Fc domain covalently linked to a chemokine domain, and a second Fc fusion protein comprising a second Fc domain covalently linked to an anticancer therapeutic antibody domain. The recombinant proteins and oncolytic viruses provided herein are contemplated to be effective for the treatment of cancer, particularly by trafficking immune cells to the tumor microenvironment.

Provided herein are modified NK-92 cells comprising a nucleic acid encoding C-C chemokine receptor type 7 (CCR7) operably linked to a promoter. Optionally, the cells further comprise a nucleic acid encoding C-C motif ligand 21 (CCL21), a nucleic acid encoding C-C motif ligand 19 (CCL19) or a combination thereof. Also provided are compositions and kits comprising the modified NK-92 cells. Provided are methods of making the modified cells and methods of treating cancer using the cells.

Disclosed herein are methods of gene editing, or endogenous suppression, of cytokines / chemokines / transcription factors secreted from chimeric antigen receptor (CAR)-bearing immune effector cell such as CAR-T cells for the mitigation of cytokine release syndrome and / or CAR-T associated neuropathy. These methods involve insertion of the CAR into a locus of a cytokine gene, blocking its expression. Also disclosed herein are (CAR)-bearing immune effector cells with CARs inserted into a locus of a cytokine gene, and methods of treatment of diseases with immunotherapy with a reduced incidence of cytokine release syndrome and / or CAR-T associated neuropathy.

The present invention discloses a novel coronavirus nano-vaccine with targeted synergistic effect, belonging to the field of vaccines. The active ingredient of the vaccine is a fusion protein, which includes the amino acid sequence of the RBD domain of the novel coronavirus. The N-terminus of the amino acid sequence of the RBD domain is connected to XCL1 through a flexible linker GSG, and the C-terminus of the RBD domain sequence is connected to the Ferritin protein through a flexible linker GSG. The purified XCL1-RBD-Ferritin can be assembled into nanoparticles of 24-mers, improving the efficiency of RBD antigen in activating DCs, especially DC1s, thereby efficiently initiating humoral and cellular immune responses.

The disclosure relates to the technical field of vaccine preparation, and in particular to an immune-enhancing delivery system formed by targeted antigen delivery by CCL11. The system further enhances immunogenicity by fusing a chemokine CCL11 with a corresponding antigen molecule, and adding a T2 label at a terminal of the antigen molecule. The system can be a nucleic acid vector or a fusion protein or the like to be applied to prevention and / or treatment of diseases caused by a corresponding antigen. According to the present invention, by utilizing a chemotactic binding capacity of CCL11 with a surface receptor of an immune cell such as a DC, different antigen proteins are transported to the surface of the DC, so that the efficiency of phagocytosis, processing and presentation of the DC on various antigen proteins is improved, and the effect of preventing and treating related diseases is improved.

The present disclosure generally relates to a viral vector carrying a synthetic cancer antigen and a chemokine. Also provided herein are compositions and uses of the viral vector for delivering, such as tagging, a tumor with the synthetic cancer antigen.

The present invention provides a pluripotent stem cell expressing the following (a) and (b): (a) an exogenous gene encoding CC chemokine receptor 2 type B(CCR2B) (b) an exogenous gene encoding CC chemokine ligand 19 (CCL19), or an NK cell derived from the pluripotent stem cell or a progenitor cell thereof.

The invention provides an engineered immune cell for jointly expressing XCL1 and Flt3l as well as preparation and application of the engineered immune cell. The XCL1 and the Flt3l are jointly expressed in the T cells at the same time, migration and functions of the DC can be remarkably promoted, interaction between the DC and the T cells is improved, and the number of TCF1 + SlamF6 + dry T cells is maintained. The engineered immune cell provided by the invention can synergistically and remarkably improve the killing effect on tumors.

Provided herein are macromolecules that conditionally induce a cellular effector function (e.g., a biological or therapeutic activity) based on the presence of a disease signature ligand, compositions comprising the same, and methods of using the same.

To provide: in the field of oncolytic viruses, in particular a recombinant rhabdovirus, such as vesicular stomatitis virus encoding a CCL21 protein in its genome; and the use of the recombinant virus in treatment of cancer, and also methods for producing such viruses.SOLUTION: The present invention provides, in the field of oncolytic viruses, in particular a recombinant rhabdovirus, such as vesicular stomatitis virus encoding a CCL21 protein in its genome. The invention further provides the use of the recombinant virus in treatment of cancer, and also methods for producing such viruses.SELECTED DRAWING: None

This disclosure provides, inter alia, genetically engineered cells having an artificial protospacer-adjacent motif (PAM) introduced via a CRISPR / Cas-mediated gene editing, and optionally, one or more modifications in a target gene. The disclosure also provides methods and compositions, including gRNAs, that can be used to make such modifications.

A chemokine mixture suitable for modulating an immune response, comprising a first chemokine, or an agonist or antagonist mutant thereof, suitable for binding to CCR4, and a second chemokine, or an agonist or antagonist mutant thereof, suitable for binding to CCR5 and / or CCR6.

Contemplated treatments and methods produce substantially increased quantities of memory T-cells and a persistent immune response by subcutaneous and / or subdermal co-administration of (1) a vector comprising a recombinant nucleic acid that encodes a cancer associated epitope, a cancer specific epitope, and / or a neoepitope, (2) an immune stimulating cytokine, and (3) a checkpoint inhibitor. Most typically, the co-administration is performed at substantially the same location, preferably within 1-21 days from each other, and the vector is an adenoviral expression vector, for example, included in a viral particle such as an AdV5 virus with a deletion of the E2b gene.

The present invention relates to novel peptides, compositions and kits comprising said peptides, for use as active ingredients for preventing or treating pain in a subject in need thereof. In vitro or ex vivo methods for modulating the expression of these peptides are also described herein.

A method of stabilizing a chemokine protein with a C-X-C or a C-C structural motif such as CXCL13 and CCL21 is provided. The method comprises the step of introducing the chemokine proteins into a solution comprising a buffer a non- ionic or amphoteric surfactant; and an aqueous chaotropic agent. A method of detecting a chemokine protein with a C-X-C or a C-C structural motif such as CXCL13 and CCL21 conjugated to antibodies thereto labelled with a fluorescent label in a solution is also provided. The method comprises the following steps: providing a test substrate comprising an elongate nitro cellulose membrane.

The specification relates to a method of manufacturing a diabetic foot patient-specific skin regeneration sheet, and a diabetic foot patient-specific skin regeneration sheet.

This disclosure provides, inter alia, genetically engineered cells having an artificial protospacer-adjacent motif (PAM) introduced via a CRISPR / Cas-mediated gene editing, and optionally, one or more modifications in a target gene. The disclosure also provides methods and compositions, including gRNAs, that can be used to make such modifications.

The invention discloses a preparation method and application of an engineered neutrophil liposome drug for enhancing an anti-tumor immune effect, and finds that the combination of a neutrophil membrane liposome carrying CXCL9 and a CAR-T cell targeting B7-H3 has a synergistic treatment effect on solid tumors such as lung cancer for the first time. The invention provides a brand new effective drug combination strategy for the treatment of solid tumors such as lung cancer, and has important scientific significance and clinical application value in the technical field of development of drugs for treating solid tumors such as lung cancer.

The present disclosure relates to CXCR3 ligands having CXCR3-expressing-cell migration-inducing activity, and specifically to amino acid modifications and amino acid sequences that are important for CXCR3-expressing-cell migration-inducing activity.

The present invention relates to immune cells expressing IL-7 (interleukin-7), CCL19 (CC Motif Chemokine Ligand 19), or a combination thereof, and compositions containing the same as active ingredients for the prevention or treatment of cancer or infectious diseases. The present invention provides a multifaceted and synergistic therapeutic effect through the complementary immune response between the patient's endogenous T cells and the infused natural killer cells by injecting only a therapeutically effective amount of immune cells other than T cells. Furthermore, the present invention also provides a significantly improved therapeutic effect when administering T cells and immune cells other than T cells, specifically natural killer cells, by allowing these different cell groups to act more intensively at the lesion site.

The invention relates to the field of biological medicine, in particular to a medicine for treating HPV infection related diseases. The invention provides antigen combinations, fusion proteins and encoding nucleic acids. The materials are used for preparing self-replicating RNA vaccines for treating cervical HPV persistent infection, intraepithelial neoplasia induced by the cervical HPV persistent infection and cervical cancer, and indications can be expanded to HPV long-term infected people. Therefore, not only can virus host cells be removed to treat long-term infection, but also precancerous lesions and cervical cancer can be treated more effectively.

The present invention relates to the technical field of vaccine preparation, and in particular to an immune-enhancing delivery system formed by targeted antigen delivery by CCL11. The system further enhances immunogenicity by fusing a chemokine CCL11 with a corresponding antigen molecule, and adding a T2 label at a terminal of the antigen molecule. The system can be a nucleic acid vector or a fusion protein or the like to be applied to prevention and / or treatment of diseases caused by a corresponding antigen. According to the present invention, by utilizing a chemotactic binding capacity of CCL11 with a surface receptor of an immune cell such as a DC, different antigen proteins are transported to the surface of the DC, so that the efficiency of phagocytosis, processing and presentation of the DC on various antigen proteins is improved, and the effect of preventing and treating related diseases is improved. The key point of the present invention is that a T2 sequence added to an antigen can enhance an immune response.

The invention relates to methods of treating a tumor in a subject by administering to the subject the following active agents: (a) interleukin- 12 (IL-12), a nucleotide expressing IL-12, or combinations thereof; and (b) c-c motif chemokine ligand 3 (CCL3), a nucleotide expressing CCL3, or combinations thereof. The invention also relates to therapeutic compositions that include the following active agents; (a) IL-12, a nucleotide expressing IL-12, or combinations thereof; and (b) CCL3, a nucleotide expressing CCL3, or combinations thereof.

The invention relates to plasmids capable of expressing a protein targeting immune cells when transformed into a lactic acid bacterial cell, wherein the protein is chosen from the group consisting of murine and human CXCL12 1α; CXCL17 and Ym1. The invention further relates to lactic acid bacteria transformed with a said plasmid, as well as the use of said lactic acid bacteria for wound healing in humans and animals.

The invention provides a novel recombinant orf virus (ORFV), the recombinant orf virus expresses a chemotactic factor CXC ligand 9, the recombinant orf virus is a strain ORFV [delta] 005-008 (expressed by ORFV [delta]) with ORFV ORFs 005-008 gene deletion, and the Cxc19 gene expressed by the recombinant orf virus is one of a mouse source, a human source and a cat source. The ORFV oncolytic virus is used as a carrier to develop a tumor immunotherapy drug ORFVdelta-Cxc19 expressing CXCL9, the CXCL9 is expressed in tumor cells by using the characteristics of virus infection, the collection of T cells in a tumor microenvironment is promoted while the tumor cells are cracked, and the anti-tumor effect of the oncolytic virus is enhanced. The invention provides a new strategy for tumor treatment.

To provide cleavable activators of CXCR3 and methods of use.SOLUTION: Disclosed is a recombinant C-X-C motif chemokine ligand (CXCL) peptide modified to introduce a cleavage site for a protease (e.g., a protease that is activated during an inflammation response). The CXCL peptide has an ability to activate CXCR3 until the protease cleaves the peptide. The proteolytic cleavage of the CXCL peptide minimizes pro-inflammatory response and inhibits the development of fibrosis. The CXCL may be CXCL10, CXCL4, CXCL9 or CXCL11.SELECTED DRAWING: None